

Denosumab (Prolia or Biosimilar)

Infusion Office Preference:	
PATIENT INFORMATION	
Date: Patient Name:	DOB:
□ NKDA Allergies:	Weight (lbs / kg): Height:
Patient Status: ☐ New to Therapy ☐ Continuing Therapy - Last Treatment Date: Next Due Date:	
PROVIDER INFORMATION	
Office Contact Name:	Office Email:
Prescribing Providers Name:	Provider NPI:
Office Address:	City: State: Zip:
Office Phone Number:	Office Fax Number:
DIAGNOSIS AND ICD 10 CODE	
☐ Osteoporosis in women or men at high risk of developing fra	octure ICD-10 Code: M81.0
□ Other Diagnosis:	ICD-10 Code:
REQUIRED DOCUMENTATION/Testing	
 □ This signed order form by the provider □ Patient demographics AND insurance info □ Clinical/Progress notes supporting primary dx 	☐ Calcium drawn and noted to be WNL and results sent☐ DEXA scan results and/or FRAX score
List Tried & Failed Therapies 1)	2)
MEDICATION ORDERS	
Denosumab 60mg SubQ every 6 months (Pharmacy to dispense based off of product availability) □ Dispense as written Prolia (no substitutions)	
SPECIAL INSTRUCTIONS	
* Referring physician is responsible for monitoring and reviewing serum Calcium level prior to dose of Prolia. ** Clinical monitoring of calcium, phosphorus, and magnesium is highly recommended in patients with severe renal impairment Adequately supplement all patients with Calcium and vitamin D. Provider Name (Print) **Physician Signature: Date:	
Provider Name (Print) **Physician Sig	nature: Date:

REFERRAL STATUS: \square New Referral \square Dose or Frequency Change \square Order Renewal

